Teva, Sanofi preclinical data

A gene expression analysis of mouse splenocytes showed that Teva's MS drug Copaxone glatiramer acetate significantly increased levels of forkhead box P3 (FOXP3) vs. generic glatiramer acetate. Teva said FOXP3 is a key factor for controlling the development and function of Treg cells, which may help suppress harmful autoimmunity in MS patients. The study also showed that the biological impact on Treg cells by glatiramer acetate was more consistent across different batches of Copaxone than across different batches of generic glatiramer acetate. However, Teva said the extent to which the impact on Treg cells might affect patient response remains unknown. Data were published in PLoS ONE. ...